Latest Articles and Analysis

Pharmaceutical industry changes to 340B implementation impact pricing and accessibility for covered entities.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

Final installment addressing 340B reform needs: transparency, accountability, and contract pharmacy concerns.

Analyzes the role of contract pharmacies and intermediaries in 340B drug distribution and patient access.

Examines how 340B program expansion correlates with declining hospital charity care for vulnerable patients.

Explores accountability mechanisms in the 340B program and oversight requirements for patient protection.

Explains why transparency in 340B operations is critical for program integrity and patient access.

Introduces the 340B Drug Discount Program: its history, purpose, and significance for medication access.

Overview of the 340B Drug Discount Program for patient advocates covering program history and key policy issues.

Calls for restoring Obama-era guidance defining 340B patient protections and enforcement mechanisms.

CANN outlines advocacy priorities for the Biden era, from 340B reform and drug pricing to HIV criminalization and health equity.